HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational-signatures

Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Germline and/or somatic mutations in BRCA1/BRCA2 in other cancer types also confer selective sensitivity to PARP inhibitors. T...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Nat Med
Κύριοι συγγραφείς: Davies, Helen, Glodzik, Dominik, Morganella, Sandro, Yates, Lucy R., Staaf, Johan, Zou, Xueqing, Ramakrishna, Manasa, Martin, Sancha, Boyault, Sandrine, Sieuwerts, Anieta M., Simpson, Peter T., King, Tari A., Raine, Keiran, Eyfjord, Jorunn E., Kong, Gu, Borg, Åke, Birney, Ewan, Stunnenberg, Hendrik G., van de Vijver, Marc J., Børresen-Dale, Anne-Lise, Martens, John W.M., Span, Paul N., Lakhani, Sunil R, Vincent-Salomon, Anne, Sotiriou, Christos, Tutt, Andrew, Thompson, Alastair M., Van Laere, Steven, Richardson, Andrea L., Viari, Alain, Campbell, Peter J, Stratton, Michael R., Nik-Zainal, Serena
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833945/
https://ncbi.nlm.nih.gov/pubmed/28288110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4292
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια